• Regenerex Pharma posted a net loss of $2.54 million for the nine months ended Dec. 31, 2025, widening from $1.12 million.
• Revenue remained absent, while the wider loss was driven by higher stock-based compensation, R&D, salaries, and consulting fees.
• Cash used in operating activities rose to $1.25 million from $340,651 in the year-ago period.
• Financing cash inflow increased to $605,934 from $340,617, mainly on higher common-stock sales.
• Management is negotiating a first State Medicaid contract, pursuing private insurer preferred status, and targeting a $5 million raise by end-September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerex Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001472375-26-000211), on August 31, 2026, and is solely responsible for the information contained therein.